title: Next-generation optimized biotherapeutics - A review and preclinical study.
abstract: Biotherapeutics have been clinically used since the 1990s. Recently, next-generation optimized biotherapeutics, which are expected to act on the same molecular target as their predecessors with further properties by antibody-drug conjugation, radiolabeling, PEGylation and glycoconjugation, are on the market. This article reviews recent next-generation optimized biotherapeutics. Moreover, since trials of protein engineering for biotherapeutics have been conducted, these preclinical approaches are also described. This article is part of a Special Issue entitled: Recent advances in molecular engineering of antibody.
authors: Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. Electronic address: ueda@phar.kyushu-u.ac.jp.
authors: Tadashi
authors: T
authors: Ueda
keywords: Antibody; Biotherapeutic; Chemical modification; Protein engineering